ABSI

Absci Corporation (ABSI) | Rumor.io

Absci

ABSI

Attention (50-day avg)0.01%

Attention rank (50-day avg)#652

Bullish sentiment (50-day avg)99%

Price to earnings ratio-11.3

Market capitalization1.6B

Earnings per share-0.77

Dividend yield (TTM)—

Revenue (annual)2.8M

Net income (annual)-115.2M

Social

What share of all stock conversation is about ABSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% 0	0% 0

Sep 17

ABSI has seen a breakout, with the stock price increasing, and the author is hopeful for more volume.
There is speculation about the reasons behind ABSI's rising price, with some users wondering if it's due to a pump or an actual increase in interest.
One user has taken a significant profit from ABSI, selling a third of their shares and locking in a 100% return, while another user sees an opportunity in the stock.

Generated by AI

Sentiment

Of the messages about ABSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +50	91.3% -7.51	98.59% -0.65	93.22% +7.66
Bearish	0% -50	8.7% +7.51	1.41% +0.65	6.78% -7.66

Bullish· Jun 24

$ABSI is breaking out nicely, with a strong uptrend from $5.08 lows, driven by positive results from its AI-designed hair loss drug.
The company's AI x bio strategy is gaining traction, with a confluence of catalysts, including positive results from $ABSI, Dario's optimism on AI x bio, and anticipation of a favorable FDA leadership change.
$ABSI has significant upside potential, with massive growth potential, major clinical catalysts ahead, and a strong momentum, making it a high-risk, high-reward play that can seriously pay off with proper management.

Bearish· Jun 24

$ABSI's recent price action may be due to the exit of $AMD money, leading to a potential sell-off.
$ABSI's current price is considered overpriced, with many expecting a significant drop below $9.
$ABSI's price is expected to decline to $7.31, with some predicting a big sell-off on the open.

Generated by AI

Topics

Of the messages about ABSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	43.75%	91.51%	22.97%
Announcements	—	56.25%	8.18%	56.2%
Analysts	—	0%	0.31%	18.39%
Earnings	—	0%	0%	2.02%
Controversies	—	0%	0%	0.42%
Macro	—	0%	0%	0%

Announcements· Jun 24

Absci Corporation ($ABSI) reports positive interim Phase 1 data for its lead candidate ABS-201, an antibody designed with AI to block the prolactin receptor, showing no serious problems in safety data from the first groups.
$ABSI secures a $100 million financing backed by prominent investors, including Eli Lilly & Company, to support the development of ABS-201 across androgenetic alopecia and endometriosis.
Absci's Integrated Drug Creation platform uses generative AI models to design full-length monoclonal antibodies, and the company is utilizing this platform to develop its AI-assisted drug discovery capabilities.

Technical Analysis· Jan 8

$ABSI has a strong setup with a powerful PR announcement and $123m in cash, boasting 20% insider ownership and 62% held by insiders.
The stock has a potential major run on $5.20 and $5.44 pivots after breaking through the $4.50 level, with room for a significant price increase.
Technical indicators, including the MACD Divergence and Vol Profile POC, are showing bullish signals, with the stock also exhibiting an inverse head and shoulders pattern and a break of the downtrend.

Generated by AI

Community

Of the messages about ABSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	13.04%	37.68%	9.93%	26.58%
Newcomers	86.96%	62.32%	90.07%	73.42%

Regulars· Aug 11

Absci Corporation has released its Q2 2022 financial results, exceeding guidance for the year with 10 new Active Programs for drug discovery activities signed YTD.
The company has enough cash to operate through 2025, leading to a significant stock price increase.
Absci's GAAP EPS of -$0.32 and revenue of $1M missed analyst expectations, resulting in a stock price decline.

Newcomers· Aug 11

Newcomers are excited about ABSI's potential as a "clean public bet" on AI-designed drugs, with Phase 1 data showing promising results.
The company's Q2 earnings report showed a significant net loss, but a substantial increase in cash reserves after a $100M raise, including a $40M investment from Eli Lilly.
ABSI's earnings report was seen as a "disaster" by some, with a widened net loss and a potential need for further funding in the next 12 months, but others see the company's potential for future growth and partnerships.

Generated by AI

News

Guggenheim reiterates Absci stock rating on endometriosis trial delay

2d agoInvesting.com

Absci plans phase 2 trial of ABS-201 for endometriosis in 2027

5d agoInvesting.com

Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027

5d agoYahoo Finance

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center

5d agoYahoo! Finance Canada

Absci (ABSI) Stock Looks Expensive Against Its Book Value

8d agoYahoo Finance

Absci at Morgan Stanley healthcare conference: AI platform meets clinical test

13d agoInvesting.com

Also Discussed

Investors talking about ABSI also mention

#	Name	Attention
1	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
2	Schrödinger, Inc.SDGR	0%-0.01
3	AbCellera Biologics Inc.ABCL	0.24%-0.06
4	EXAI - Exscientia plc	——
5	Twist Bioscience CorporationTWST	0%-0.02
6	Relay Therapeutics Inc.RLAY	0%new
7	Beam Therapeutics IncBEAM	0.02%+0.02
8	KRON - Kronos Bio, Inc.	——
9	Prime Medicine, Inc.PRME	0%-0.01
10	AKYA - Akoya Biosciences, Inc.	——

Absci Corporation

Healthcare
Biotechnology

Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.

Website

Location

18105 SE Mill Plain Boulevard

Vancouver, WA, 98683

United States

Social

What share of all stock conversation is about ABSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% -0.01	0% 0	0% 0

Sep 17

ABSI has seen a breakout, with the stock price increasing, and the author is hopeful for more volume.
There is speculation about the reasons behind ABSI's rising price, with some users wondering if it's due to a pump or an actual increase in interest.
One user has taken a significant profit from ABSI, selling a third of their shares and locking in a 100% return, while another user sees an opportunity in the stock.

Generated by AI

Sentiment

Of the messages about ABSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +50	91.3% -7.51	98.59% -0.65	93.22% +7.66
Bearish	0% -50	8.7% +7.51	1.41% +0.65	6.78% -7.66

Bullish· Jun 24

$ABSI is breaking out nicely, with a strong uptrend from $5.08 lows, driven by positive results from its AI-designed hair loss drug.
The company's AI x bio strategy is gaining traction, with a confluence of catalysts, including positive results from $ABSI, Dario's optimism on AI x bio, and anticipation of a favorable FDA leadership change.
$ABSI has significant upside potential, with massive growth potential, major clinical catalysts ahead, and a strong momentum, making it a high-risk, high-reward play that can seriously pay off with proper management.

Bearish· Jun 24

$ABSI's recent price action may be due to the exit of $AMD money, leading to a potential sell-off.
$ABSI's current price is considered overpriced, with many expecting a significant drop below $9.
$ABSI's price is expected to decline to $7.31, with some predicting a big sell-off on the open.

Generated by AI

Topics

Of the messages about ABSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	43.75%	91.51%	22.97%
Announcements	—	56.25%	8.18%	56.2%
Analysts	—	0%	0.31%	18.39%
Earnings	—	0%	0%	2.02%
Controversies	—	0%	0%	0.42%
Macro	—	0%	0%	0%

Announcements· Jun 24

Absci Corporation ($ABSI) reports positive interim Phase 1 data for its lead candidate ABS-201, an antibody designed with AI to block the prolactin receptor, showing no serious problems in safety data from the first groups.
$ABSI secures a $100 million financing backed by prominent investors, including Eli Lilly & Company, to support the development of ABS-201 across androgenetic alopecia and endometriosis.
Absci's Integrated Drug Creation platform uses generative AI models to design full-length monoclonal antibodies, and the company is utilizing this platform to develop its AI-assisted drug discovery capabilities.

Technical Analysis· Jan 8

$ABSI has a strong setup with a powerful PR announcement and $123m in cash, boasting 20% insider ownership and 62% held by insiders.
The stock has a potential major run on $5.20 and $5.44 pivots after breaking through the $4.50 level, with room for a significant price increase.
Technical indicators, including the MACD Divergence and Vol Profile POC, are showing bullish signals, with the stock also exhibiting an inverse head and shoulders pattern and a break of the downtrend.

Generated by AI

Community

Of the messages about ABSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	13.04%	37.68%	9.93%	26.58%
Newcomers	86.96%	62.32%	90.07%	73.42%

Regulars· Aug 11

Absci Corporation has released its Q2 2022 financial results, exceeding guidance for the year with 10 new Active Programs for drug discovery activities signed YTD.
The company has enough cash to operate through 2025, leading to a significant stock price increase.
Absci's GAAP EPS of -$0.32 and revenue of $1M missed analyst expectations, resulting in a stock price decline.

Newcomers· Aug 11

Newcomers are excited about ABSI's potential as a "clean public bet" on AI-designed drugs, with Phase 1 data showing promising results.
The company's Q2 earnings report showed a significant net loss, but a substantial increase in cash reserves after a $100M raise, including a $40M investment from Eli Lilly.
ABSI's earnings report was seen as a "disaster" by some, with a widened net loss and a potential need for further funding in the next 12 months, but others see the company's potential for future growth and partnerships.

Generated by AI

Absci

Social

Sep 17

Bullish· Jun 24

Bearish· Jun 24

Announcements· Jun 24

Technical Analysis· Jan 8

Regulars· Aug 11

Newcomers· Aug 11

Guggenheim reiterates Absci stock rating on endometriosis trial delay

Absci plans phase 2 trial of ABS-201 for endometriosis in 2027

Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci (ABSI) Stock Looks Expensive Against Its Book Value

Absci at Morgan Stanley healthcare conference: AI platform meets clinical test

Also Discussed

Absci Corporation

Company Information

Location

Guggenheim reiterates Absci stock rating on endometriosis trial delay

Absci plans phase 2 trial of ABS-201 for endometriosis in 2027

Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci (ABSI) Stock Looks Expensive Against Its Book Value

Absci at Morgan Stanley healthcare conference: AI platform meets clinical test

Also Discussed

Social

Sep 17

Bullish· Jun 24

Bearish· Jun 24

Announcements· Jun 24

Technical Analysis· Jan 8

Regulars· Aug 11

Newcomers· Aug 11